. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Mayo Clin Proc. 2013 Feb;88(2):10.1016/j.mayocp.2012.11.007. doi: 10.1016/j.mayocp.2012.11.007

Table 4.

Bleeding Outcomes in Subset of Patients Not Taking Warfarin

Characteristic	No Warfarin at Admission Patient Group^a		P value	RR (95% CI)^b
Characteristic	Clopidogrel (n=39)	Control (n=65)	P value	RR (95% CI)^b
Hemoglobin values
Nadir, g/dL	9.0 (1.2)	8.9 (1.0)	.43
Delta, g/dL	2.9 (1.7)	3.6 (1.5)	.04
Delta >4 g/dL	11 (28)	23 (35)	.45	0.80 (0.44-1.45)
Major bleeding event	2 (5)	2 (3)	.63	1.67 (0.24-11.36)
Combined bleeding outcome	19 (49)	32 (49)	.96	0.99 (0.66-1.48)
pRBCs
Total units	2.1 (2.1)	1.8 (2.2)	.50
Patients requiring >3 units	9 (23)	12 (18)	.57	1.25 (0.58-2.70)

Values are mean (SD) or No. of patients (%).

RR only provided for categorical data.

NR: RR not reported since no patient in the clopidogrel group received vitamin K during hospitalization.